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Abstract The presenilin-I (PS-I) gene on chromosome 14 
carries mutations which cosegregate with early-onset familial 
Alzheimer's disease. We quantified PS-1 mRNA in post-mortem 
mid-temporal and superior frontal cortices from 14 Alzheimer's 
disease subjects, 9 non-demented controls and 5 subjects with 
other neurological diseases using solution hybridisation-RNase 
protection assay. APP and APLP2 mRNAs had previously been 
quantified in these samples (Johnston et al. (1996) Mol. Brain 
Res., in press) and subjects were apolipoprotein E (APOE) 
genotyped. There were no significant differences between PS-1 
mRNA levels per pg total RNA in mid-temporal or superior 
frontal cortices of the Alzheimer's disease subjects, compared to 
controls. PS-1 mRNA levels corresponded to 10% of total APP 
and 30% of APLP2 mRNA levels, and were not significantly 
affected by age, post-mortem delay, tissue pH, or APOE 
genotype. PS-1 mRNA showed significant positive correlations 
with APP and APLP2 mRNA levels in mid-temporal cortex and 
with APP mRNA in superior frontal cortex. This may reflect a 
co-regulation of the expression of these genes, or the fact that 
they are expressed in similar neuronal populations. 
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1. Introduction 
membrane protein [5]. Full length PS-1 is 467 amino acids in 
size and PS-1 RNA is alternatively spliced to produce at least 
two other isoforms which would encode proteins with 463 [11] 
and 374 [12] amino acids. A range of shorter mRNA tran- 
scripts have also been detected in post-mortem human brain 
using RT-PCR techniques, although full length PS-1 was the 
most abundant isoform found in this tissue [13]. PS-1 expres- 
sion has been detected in several regions of human brain 
[5,11-15] and in situ hybridisation studies indicate that this 
expression is largely neuronal [14,15]. An immunohistochem- 
ical study of PS-I in mouse brain confirmed this finding, re- 
vealing mainly neuronal, intracellular nd granular PS-1 stain- 
ing, suggestive of a vesicular location [16]. 
The aim of the present study was to determine whether 
altered PS-1 mRNA expression is a feature of Alzheimer's 
disease pathology. We established a quantitative solution hy- 
bridisation-RNase protection assay to determine PS-1 mRNA 
levels in mid-temporal nd superior frontal cortices from a 
series of Alzheimer's disease subjects and matched controls. 
We had previously quantified total amyloid precursor protein 
(APP), APP containing the Kunitz-type protease inhibitor in- 
sert (APP KPI) and amyloid precursor-like protein 2 (APLP2) 
mRNA levels in these subjects [1]. In addition, since inheri- 
tance of the apolipoprotein E (APOE) e4 allele increases the 
risk of developing Alzheimer's disease [17,18], we genotyped 
the subjects in order to establish whether any relationship 
existed between APOE genotype and PS-I mRNA levels. 
Several molecules which are likely to be involved in the 
aetiology of Alzheimer's disease have now been identified. 
The genetic heterogeneity of this disease suggests that a num- 
ber of mechanisms may be involved, which eventually con- 
verge on a final common pathological cascade. In a sub-group 
of familial Alzheimer's disease, pathogenic mutations are 
present in the amyloid precursor protein (APP) gene. These 
mutations alter the production of a metabolite of APP, AI342, a 
peptide component of the amyloid plaques which characterise 
Alzheimer's disease neuropathology [24]. Recently, a gene on 
chromosome 14, S182 or presenilin-1 (PS-1), was identified 
and shown to carry mutations which cosegregate with early- 
onset familial Alzheimer's disease [5]. A homologous gene on 
chromosome 1, presenilin-2, also carries mutations which are 
pathogenic for the disease [6,7]. To date, over 30 pathogenic 
mutations have been identified on the PS-1 gene [8]. The nor- 
mal function of PS-I, or its role in the aetiology of Alzhei- 
mer's disease, have not yet been determined, although there 
are indications that the PS-1 mutations, like the APP muta- 
tions, increase A~42 production and deposition [9,10]. The 
protein sequence of PS-I contains even hydrophobic, poten- 
tially transmembrane regions, suggestive of an integral mem- 
brane protein such as a receptor, channel protein or structural 
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2. Materials and methods 
2.1. Post-mortem brain tissue 
Clinical information about the subjects included in this study has 
been presented in detail elsewhere [1]. Brain tissue was obtained via 
the rapid autopsy program of The Netherlands Brain Bank. Regions 
of mid-temporal cortex (gyrus temporalis medialis) and superior fron- 
tal cortex (gyrus frontalis superior) were dissected from 14 Alzhei- 
mer's disease subjects, 9 non-demented control subjects with no his- 
tory of neurological or psychiatric disorders, and a positive disease 
control group of 5 individuals with other neurological diseases (Par- 
kinson's disease, Lewy body disease and progressive supranuclear 
palsy). The diagnosis of 'probable AD', based on NINCDS-ADRDA 
criteria [19], was confirmed by extensive post-rnortem neuropatholog- 
ical examination using conventional histopathological staining tech- 
niques on formalin-fixed tissue. Diagnosis was based on the presence 
and distribution of plaques and tangles, and the extent of disruption 
of the fibre pattern (dystrophic neurites) in the hippocampus, superior 
frontal area (area 10), orbito-frontal cortex (area 11), superior tem- 
poral cortex (area 22), cortex of the temporal pole (area 38), the 
superior parietal (area 7), inferior parietal (area 40) and the cortex 
of the occipital lobe (area 17 and 18). Brain pH values were deter- 
mined on ventricular CSF at autopsy to provide an indication of 
agonal status [2~22]. Mean tissue pH + S.D. was 6.51 _+ 0.35 for the 
Alzheimer's disease subjects; 6.82+0.66 for the non-demented con- 
trols; and 6.48+0.22 for the positive disease controls. The groups 
were also matched for age (age+S.D. was 77.7+9.7 years for the 
Alzheimer's disease subjects; 76.0_ +14.7 years for the non-demented 
controls; and 81.4_+ 12.3 years for the positive disease controls). Tis- 
sue was dissected fresh and the meninges and white matter emoved 
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280 J.A. Johnston et al./FEBS Letters 394 (1996) 279-284 
before snap freezing under liquid nitrogen and storage at -70°C. The 
period between time of death and freezing of the tissue (post-mortem 
delay) was kept as short as possible, but was significantly longer in the 
non-demented control group (374_+ 102 min) than in the Alzheimer's 
disease group (266 + 68 min; p-<0.01, Student's t-test). The post-mor- 
tem delay for the positive disease control group was 271 _+ 64 min (no 
significant difference from non-demented controls). 
2.2. Total nucleic acid extraction 
Total nucleic acid (TNA) was prepared by digestion of homoge- 
nised brain tissue (100-200 mg) with proteinase K (IBI, 200 lag/ml) 
and subsequent extraction with phenol/chloroform, as described [23]. 
TNA was dissolved in 0.2 x SET (0.2% SDS, 2 mM EDTA and 4 mM 
Tris, pH 7.6). TNA and DNA concentrations were determined by 
spectrophotometry and using Hoechst 33258 fluorimetry [24], respec- 
tively. RNA concentrations were calculated by subtracting the DNA 
concentrations from the TNA concentrations. 
2.3. Probe synthesis 
Radiolabelled antisense RNA probe, designed to hybridise to posi- 
tions 384-554 of PS-1 (S182 coding sequence, accession o. L42110), 
was transcribed in vitro from a DNA template generated by polymer- 
ase chain reaction (PCR) as described below. 1 lag total RNA ex- 
tracted from a lymphoblastoid cell line was reverse transcribed using 
M-MLV reverse transcriptase (Gibco, BRL) in a final volume of 50 
lal, according to the manufacturer's instructions. 1 lal of this reaction 
product was then used as template for PCR amplification of positions 
203-618 of PS-I with primers 5'-AAGAGGCTTTGTTTTCTGTG 
and 5'-CTCGGTATCTTCTGTGAATG in a final volume of 25 lal 
for 30 cycles (annealing temperature 52°C). This PCR product was 
diluted 100-fold, and 1 gl used as template for a second PCR (100 lal) 
where each primer encoded an RNA polymerase promoter (either SP6 
or T7), in addition to a 20 nucleotide complementary egion. The 
primers used were 5'-TAATACGACTCACTATA GGGGATC 
CACCCTGAGCCATTATCTAA (T7 promoter underlined) and 5' 
(biotinylated)-ATTTAGGTGACACTATA GGATCCC TGACT- 
TAATGGTAGCC ACGA (SP6 promoter underlined) for 30 cycles 
(annealing temperature 53°C), producing a 218 base pair product. 
Single-stranded DNA was prepared using streptavidin-coated mag- 
netic Dynabeads (Dynal, Oslo) and the PCR product verified by se- 
quencing using the Sequenase kit, version 2.0 (USB) according to the 
manufacturer's instructions. 
The PCR product was purified using a Wizard PCR Preps DNA 
purification system (Promega) before use as template DNA for in 
vitro transcription of sense and antisense RNA. Radiolabelled anti- 
sense RNA probe was transcribed from approx. 4 ng PCR template in 
the presence of [35S]CTP (Du Pont Scandinavia) using SP6 RNA 
polymerase, according to the manufacturer's instructions (Riboprobe 
Gemini 11 system, Promega). Template DNA was degraded by incu- 
bation with 1 unit RQ1 ribonuclease-free DNase (Promega) for 30 
min at 370C, and unincorporated nucleotides removed by fractiona- 
tion through a disposable Nick column packed with Sephadex G-50 
(Pharmacia, Sweden). Intact transcripts were ethanol precipitated and 
dissolved in 500 lal 0.2 x SET (see Section 2.2). Probe concentration 
was determined by trichloroacetic a id precipitation, capture on glass 
fibre filters (GF/C, Whatman), and scintillation counting. Probe in- 
tegrity was also checked by polyacrylamide gel electrophoresis (see 
Section 2.5). 
Sense standard RNA was transcribed from approx. 30 ng purified 
PCR product using T7 RNA polymerase, and template DNA de- 
graded using 10 units RQ1 ribonuclease-free DNase (Promega) as 
described above. Intact transcripts, identified by their absorbance at 
260 nm, were purified by two consecutive fractionations through Se- 
phadex G-50 columns. The final concentration of intact sense RNA 
transcripts was determined spectrophotometrically. Antisense and 
sense RNA transcripts were aliquoted and stored at -80°C until use. 
2.4. Solution hybridisation-RNase protection assay 
This assay was carried out as described in detail elsewhere for APP 
and APLP2 mRNA quantification [23]. Briefly, 35S-labelled antisense 
RNA probe was hybridised in solution with either increasing amounts 
of unlabelled sense in vitro transcribed RNA, enabling construction of 
a standard curve; or with TNA sample. Hybridisations were run for 
18 h at 75°C in the presence of 25% formamide, 0.75 mM DTT, 0.6 M 
NaCI, 20 mM Tris and 4 mM EDTA in a reaction volume of 40 lal, 
covered with paraffin oil. Non-hybridised RNA was then degraded by 
incubation with 1 ml RNase T1 (2 gg/ml), RNase A (40 lag/ml) and 
salmon sperm DNA (100 gg/ml) (Sigma) at 37°C for 45 min. Ribo- 
nuclease-resistant hybrids were precipitated with 10% trichloroacetic 
acid, captured on Whatman GF/C filters, and quantified by scintilla- 
tion counting. 
The amount of specific mRNA present was calculated by compar- 
ison with the standard curve, using a correction factor of 1.08 to 
account for the difference in length of probe/standard RNA (185 
bp) and probe/endogenous mRNA (171 bp) hybrids. Hybridisation 
signal was thus converted to the equivalent number of moles of stand- 
ard RNA, indicating the number of copies of PS-1 mRNA detected, 
and the results expressed as a function of either the DNA or total 
RNA content of the sample. 
2.5. Polyacrylamide gel electrophoresis of probes and nuclease-resistant 
hybrids 
Probe (50000 cpm) was hybridised with either standard RNA (5 or 
10 pg) or 68 lag TNA (containing 40 lag total RNA) extracted from 
control superior frontal cortex and treated with ribonuclease as de- 
scribed in Section 2.4. SDS (0.6%) and Proteinase K (300 lag/ml) were 
added and incubated at 37°C for 30 rain. The hybrids were then 
phenol/chloroform extracted, precipitated with 99.5% ethanol, dis- 
solved in loading buffer (95% formamide, 20 mM EDTA) and run 
on a 5% denaturing polyacrylamide gel. The gel was soaked in Am- 
plify (Amersham, UK) fluorographic reagent for 30 min prior to 
visualisation of the bands by exposure of Biomax MR film (Kodak) 
to the dried gel. 
2.6. APOE genotyping 
DNA was extracted from 25 mg frozen brain tissue using the 
QIAamp Tissue kit (Qiagen). APOE genotype was determined by 
minisequencing reactions on solid-phase bound DNA using the Affi- 
gene APOE kit (Sangtec Medical, Sweden). 
3. Results 
3.1. Methodological experiments 
A representative standard curve, generated by hybridising 
increasing amounts (1 to 10 pg) of standard RNA with a fixed 
amount  (15 000 cpm) of radiolabelled antisense riboprobe, is 
shown in Fig. 1. A linear increase in hybridisation signal was 
seen using up to 50 pg standard RNA under these hybridisa- 
tion conditions. The addition of increasing amounts of TNA 
sample also produced the predicted linear increase in hybridi- 
sation signal. The reproducibil ity of the assay was examined 
by running one TNA sample in duplicate on five different 
occasions and calculating the coefficient of variation (S.D. 
expressed as a percentage of the mean value). The coefficient 
of variation for this assay was 3.2%. 
The integrity and size of the PS-1 probe, standard and 
protected probe following hybridisation with either standard 
RNA or TNA sample were established by polyacrylamide gel 
electrophoresis a described in Section 2.5. Probes and hybrids 
were of the expected sizes and no extra bands or smears in- 
dicating unspecific hybridisation or contaminat ion with ribo- 
nuclease were seen (Fig. 2). 
3.2. PS-1 mRNA in Alzheimer's disease and control cortex 
The levels of PS- 1 mRNA detected in the mid-temporal and 
superior frontal cortices of the Alzheimer's disease and con- 
trol subjects are presented in Table 1. The results are ex- 
pressed as copies of PS-1 mRNA detected per pg total 
RNA or per pg DNA present in the TNA sample. There 
were no significant differences between the number of PS-1 
mRNA copies detected per pg total RNA in the mid-temporal 
and superior frontal cortices of the Alzheimer's disease sub- 
jects, as compared to either the non-demented or positive 
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Fig. 1. A typical standard curve for the PS-1 solution hybridisation- 
RNase protection assay. Radiolabelled PS-1 riboprobe was hybri- 
dised with increasing amounts of PS-1 sense standard RNA. The 
equation of the line generated in each assay was used to convert he 
sample hybridisation signals to pg PS-1 mRNA. 
disease control groups. Expression of the results as a function 
of tissue DNA content, however, revealed a significantly re- 
duced number of PS-1 mRNA copies in the Alzheimer's dis- 
ease subjects, compared to non-demented controls, in both 
mid-temporal nd superior frontal cortices (p<-0.01, Student's 
t-test). The differences seen when results were expressed per pg 
total RNA or DNA in the sample appeared to reflect differ- 
ences between the study groups in the total RNA and DNA 
yields per mg wet weight issue (Table 1), as discussed in detail 
elsewhere [1]. Briefly, the DNA yield per mg wet weight issue 
was significantly higher in the Alzheimer's disease mid-tem- 
poral and superior frontal cortices than in the non-demented 
controls (0---0.05, Student's t-test), while the total RNA yield 
was unaffected. In contrast, the total RNA yield per mg wet 
weight tissue was significantly lower in the positive disease 
controls than in the non-demented controls in both cortical 
regions (p-<0.05, Student's t-test) while the DNA yield was 
unaltered. 
3.3. Comparison of PS-1, APP and APLP2 mRNA levels 
We compared the PS-I mRNA levels with our recently 
reported APP/APLP2 mRNA data in these samples [1] to 
determine the relative levels of expression of these genes. 
Two probes were used to detect APP, one which hybridised 
to all the reported isoforms, and one which only detected the 
isoforms encoding the kunitz-type protease inhibitor (KPI) 
domain. PS-1 mRNA was present at lower levels than both 
APP and APLP2 in cerebral cortex, at approx. 10% of total 
APP, 14% of APP KPI and 30% of APLP2 mRNA in both 
mid-temporal nd superior frontal cortices. These ratios were 
not altered in the Alzheimer's disease group as compared to 
non-demented or positive disease controls. 
We also analysed the data for potential correlations be- 
tween the expression of PS-1 and APP or APLP2 in both 
the Alzheimer's disease and control groups, as shown in 
Fig. 3. Interestingly, we found significant positive correlations 
between PS-1 mRNA levels and total APP, APP KPI and 
APLP2 mRNA levels (per pg total RNA) in mid-temporal 
cortex of both the Alzheimer's disease and control subjects. 
Correlation coefficients (r) ranged from 0.58 to 0.86 (p-<0.05, 
Fisher's r to z test). Similarly, in the superior frontal cortex, 
the levels of PS-1 mRNA correlated significantly with total 
APP and APP KPI mRNAs (r values between 0.61 and 0.75; 
p<-0.02, Fisher's r to z test). 
Significant correlations were also found when the specific 
mRNA levels were expressed as a function of sample DNA 
content. PS-1 mRNA levels showed positive correlations to 
total APP, APP KPI and APLP2 mRNA (per pg DNA) levels 
in both cortical regions of the Alzheimer's disease and control 
subjects (r values between 0.56 and 0.85; p<-0.05, Fisher's r to 
z test,). 
3.4. Effect of APOE genotype 
The PS-1 mRNA levels detected were grouped according to 
a b c d e f 
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Fig. 2. Polyacrylamide g l electrophoresis of radiolabelled riboprobe 
and nuclease resistant hybrids. Experiments were performed as de- 
scribed in Section 2.5. Lane a, PS-1 standard RNA, transcribed in
the presence of [35S]CTP in order to allow visualisation (202 bases). 
The standard RNA used in all other experiments was transcribed in
the absence of [zsS]CTP as described in Section 2.3. Lane b, PS-1 
probe alone (202 bases). Both probe and standard RNA were intact 
and of the theoretically predicted size. Ribonuclease-protected probe 
following hybridisation with PS-I standard RNA was run in lanes c 
(5 pg standard) and d (10 pg standard). The length of the probe 
protected by standard RNA was 185 bases. Ribonuclease-protected 
probe following duplicate hybridisations with 68 lag TNA extracted 
from control superior frontal cortex was run in lanes e,f. The length 
of the probe protected by sample mRNA was 171 bases. The band 
sizes indicated were confirmed by comparison with radiolabelled 
RNA transcribed from the Riboprobe Gemini positive control plas- 
mid and other previously characterised riboprobes. 
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APOE genotype for Alzheimer's disease and control subjects 
separately. Eight of the 14 Alzheimer's disease subjects carried 
at least one APOE e4 allele, compared with 4 of the 14 con- 
trol subjects. The Alzheimer's disease subjects with at least 
one APOE e4 allele tended to have lower levels of PS-1 
mRNA in mid-temporal cortex than subjects with the 
APOE e3/3 genotype (0.92 _ 0.21 versus 1.40 _+ 0.60), although 
this difference failed to reach statistical significance (p = 0.06, 
unpaired t-test). This trend was absent when the results were 
expressed per pg DNA in the sample and was not seen for the 
control groups or in superior frontal cortex. 
3.5. Effects of age, post-mortem delay and tissue pH 
Data for the Alzheimer's disease and control groups were 
analysed separately to determine potential effects of post-mor- 
tern delay, age, tissue pH and brain weight on the levels of PS- 
I mRNA. There were no significant correlations between PS-1 
mRNA levels in mid-temporal nd superior frontal cortices 
and either age, tissue pH, brain weight or post-mortem delay. 
4. Discussion 
The aim of the present study was to investigate whether PS- 
I mRNA levels are altered in mid-temporal or superior fron- 
tal cortices affected by Alzheimer's disease. This is to our 
knowledge the first systematic quantitative study of PS-1 
mRNA expression i  a series of Alzheimer's disease and con- 
trol post-mortem brains. The RNA-RNA solution hybridisa- 
tion-RNase protection assay described provides a sensitive 
and reproducible method for quantification of PS-1 mRNA 
in total nucleic acid samples. The inclusion of a standard 
curve enables absolute rather than relative quantification 
and simultaneously corrects for inter-assay variability, making 
the method ideal for analysing large sample series [23]. The 
amount of PS-1 mRNA detected was expressed both as a 
function of the total RNA in the sample, indicating its con- 
tribution to the RNA pool, and as a function of the sample 
DNA content, indicating how much PS-1 mRNA was present 
per cell sampled, as each cell has a standard amount of DNA. 
We did not identify any significant differences between the 
levels of PS-1 mRNA per pg total sample RNA in mid-tem- 
poral or superior frontal cortices of the Alzheimer's disease 
and control groups. This indicates that PS-1 mRNA levels are 
not invariably altered in Alzheimer's disease cerebral cortex, 
although further investigation will be required to determine 
whether PS-1 RNA splicing is altered in the disease, as sug- 
gested recently [13]. It is also possible that PS-1 expression is
affected by the presence of pathogenic PS-1 mutations [25]. 
When the results were expressed as a function of sample 
DNA content, the Alzheimer's disease subjects had lower lev- 
els of PS-1 mRNA than the control subjects in both mid- 
temporal and superior frontal cortices, indicating reduced lev- 
els of PS-1 mRNA per cell in the Alzheimer's disease tissue. 
It should be noted, however, that higher DNA yields were 
obtained per mg Alzheimer's disease tissue than control tissue, 
which we have speculated may be due to increased cell density 
resulting from atrophic hanges, combined with compromised 
neuronal activity as a result of the neurodegenerative process 
[1]. These results, taken together, indicate that the PS-1 
mRNA contribution to the cortical mRNA pool (copies per 
pg total RNA), is not affected in Alzheimer's disease, while 
the level of detectable PS-1 per cell sampled (copies per pg 
total DNA), is reduced. 
We have previously used solution hybridisation-RNase pro- 
tection assays to quantify the levels of APP and APLP2 
mRNA in the same series of samples used in the present study 
[1]. Two probes were used to detect APP, one which hybri- 
dised to all the reported isoforms, and one which only de- 
tected the isoforms encoding the KPI region. Briefly, total 
APP and APLP2 mRNA levels were significantly reduced in 
Alzheimer's disease mid-temporal, but not superior frontal 
cortex, suggesting that regional reductions in these mRNAs 
correlate with severity of disease pathology. In addition, a 
small significant increase in the proportion of APP KPI 
mRNA was seen in both cortical regions in Alzheimer's dis- 
ease, although it is unclear whether this occurs early in the 
disease process, predisposing to A~ production and aggrega- 
tion, or reflects later events uch as gliosis and neuronal cell 
death. The present study showed that PS-1 mRNA was pres- 
ent at lower levels than both APP and APLP2 in cerebral 
cortex, corresponding to 10% of total APP and 30°/,, of 
APLP2 mRNA. The relationship between APP/APLP2 and 
PS-1 mRNA levels was not significantly altered in the Alzhei- 
mer's disease group as compared to either of the control 
groups. 
We also identified significant positive correlations between 
PS-1 mRNA levels and total APP, APP KPI and APLP2 
mRNA levels in mid-temporal cortex. Similarly, in superior 
frontal cortex, the levels of PS-I mRNA correlated with total 
APP and APP KPI mRNAs. These observations may indicate 
Table 1 
Levels of presenilin-I mRNA in Alzheimer's disease and control cortices 
Copies/pg RNA Copies/pg DNA ktg RNA/mg tissue txg DNA/mg tissue 
Mid-temporal cortex 
Alzheimer's disease (n = 14) 
Non-demented controls (n = 8) 
Positive disease controls (n = 4) 
Superior frontal cortex 
Alzheimer's disease (n = 14) 
Non-demented controls (n = 9) 
Positive disease controls (n = 5) 
1.13+0.47 1.28+0.34 h 0.83+0.15 0.71+0.17 a 
1.28 + 0.35 1.75 + 0.35 0.79 + 0.06 0.58 + 0.12 
1.25 + 0.39 1.37 + 0.24 0.59 + 0.06 b 0.51 + 0.08 
1.38 + 0.47 1.41 + 0.38b 0.69 + 0.08 0.69 + 0.13 ~ 
1.40 + 0.42 1.98 + 0.49 0.75 + 0.11 0.52 + 0.09 
1.42 + 0.31 1.46 + 0.32* 0.63 + 0.05 a 0.63 + 0.09 
Results represent the mean (+ S.D.) levels of presenilin-1 mRNA in Alzheimer's disease, non-demented control and positive disease control subjects 
(number of subjects indicated in parentheses). Each sample was assayed in duplicate as described in Section 2 and the mean value used in 
subsequent calculations. Significance l vels are shown for the comparison of the group indicated with the non-demented controls (ap-<0.05, 
~'p-<0.01), Student's t-test. 
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Fig. 3. Correlations between PS-1 and APP/APLP2 mRNA levels in cerebral cortex PS-1 mRNA levels, expressed ascopies per pg total RNA, 
are shown plotted against otal APP mRNA, APP KPI mRNA and APLP2 mRNA levels for the Alzheimer's disease (e) and control subjects 
(©). The regression plot is represented bya solid line for the Alzheimer's disease subjects, and by a dashed line for the control subjects. Corre- 
lation coefficients (r) are shown for each group and the significance l vels for Fisher's r to z test are indicated where *p-<0.05, **p<-0.01 and 
***p<--0.001. 
a co-regulation of the expression of these genes. Some of the 
speculation around the potential function of PS-1 has focused 
on its homology to C. elegans genes, including spe-4, involved 
in spermatogenesis [5], and a stronger homology to sel-12, a 
gene involved in intercellular signalling and important in vul- 
val development [26]. Sel-12, a nine-transmembrane protein, 
interacts with a single membrane spanning protein, lin-12. 
This has led to the proposal that PS-1 interacts with APP in 
a similar fashion [27], in which case a co-regulation of their 
expression may be important. Alternatively, the correlations 
between PS-1, APP and APLP2 mRNA levels in cerebral 
cortex may reflect the fact that these genes seem to be ex- 
pressed in similar neuronal populations [16]. 
We investigated whether APOE genotype had any influence 
on the levels of PS-1 mRNA present in mid-temporal nd 
superior frontal cortices, since the mechanism by which in- 
heritance of the APOE e4 allele increases usceptibility to 
Alzheimer's disease is unclear [17,18]. APOE genotype did 
not affect PS-1 mRNA levels detected in this study, suggesting 
that its role in the aetiology of Alzheimer's disease is not 
exerted at the level of PS-1 mRNA expression. 
In summary, the present study shows that PS-1 mRNA 
levels are not grossly altered in Alzheimer's disease mid-tem- 
poral and superior frontal cortices. The PS-I mRNA levels 
detected in these brain regions corresponded to 10% of total 
APP and 30% of APLP2 mRNA levels. The positive correla- 
tions observed between PS-1 mRNA, APP and APLP2 
mRNA levels in mid-temporal nd superior frontal cortices 
are interesting, although further work will be required to de- 
termine whether this reflects a true co-regulation of the ex- 
pression of these genes, or the fact that they are expressed in 
similar neuronal populations. 
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